Adjunct extended-release valproate semisodium in late life schizophrenia

International Journal of Geriatric Psychiatry

Volumn 23, Issue 2, 2008, Pages 142-147

  Sajatovic, Martha ^a,e   Coconcea, Nicoleta ^a,b   Ignacio, Rosalinda V ^c,d   Blow, Frederic C ^c,d   Hays, Robert W ^b   Cassidy, Kristin A ^a   Meyer, William J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NorthEast Ohio Health Services   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anticonvulsants; Elderly; Schizophrenia; Valproate semisodium

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TIOTIXENE; VALPROATE SEMISODIUM;

ABSCESS; ADD ON THERAPY; ADULT; ADVERTIZING; AGED; ARTICLE; BEDTIME DOSAGE; BODY MOVEMENT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; GERIATRIC DEPRESSION SCALE; GERONTOPSYCHIATRY; HUMAN; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT REFERRAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SELF REPORT; SIDE EFFECT; SINGLE DRUG DOSE; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ADJUVANTS, PHARMACEUTIC; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; GERIATRIC PSYCHIATRY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; VALPROIC ACID;

EID: 39749196261     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1854     Document Type: Article

References (33)

1. Anderson GD. 1998. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32: 554-563.
2. Barnes TRE. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
3. Basan A, Kissling W, Leucht S. 2004. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 70(1): 33-37.
4. Calvo R, Carlos R, Erill S. 1986. Differential effects of valproic acid on the serum protein binding of lorazepam and diazepam. Int J Clin Pharmacol Res 6(3): 213-215.
5. Casey DE, Daniel DG, Wassef AA, et al. 2003. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28(1): 182-192.
6. Centers for Disease Control (CDC). 2003. Trends in aging - United States and Worldwide. MMWR Morbidity and Mortality Weekly Report 52(6): 101-104; 106.
7. Citrome L, Casey DE, Wozniak P, et al. 2004. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 55(3) 290-294.
8. Citrome L, Josiassen R, Bark N, et al. 2005. Pharmacokinetics o aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 45(1): 89-93.
9. Citrome L, Levine J, Allingham B. 2000. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994-1998. Psychiatr Serv 51(5): 634-638.
10. Citrome L, Tremeau F, Wynn PS, et al. 2004. A study of the safety efficacy, and tolerability of switching form the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol 24(3): 255-259.
11. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patents for the clinician. J Psychiatr Res 12(3): 189-198.
12. Fuller M, Sajatovic M. 2007. Drug Information Handbook of Prychiatry, 6th edn. Lexi-Comp: Hudson, OH.
13. Gobbi G, Gaudreau PO, LeBlanc N. 2006. Efficacy of topiramate valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 26(5): 467-473.
14. Ichikawa J, Chung YC, Dai J, Meltzer HY. 2005. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortex dopamine release. Brain Res 1052(1): 56-62.
15. Jeste DV, Alexopoulos S, Bartels S, et al. 1999. Consensus statement on the upcoming crisis in geriatric mental health. Arch Gen Psychiatry 56(9): 848-853.
16. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2): 261-276.
17. Jones PB, Barnes TRE, Davies L, et al. 2006. Randomized controlled trial of the effect on quality of life of second vs. first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 63(10): 1079-1087.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12): 1209-1223.
19. Porsteinsson AP, Tariot PN, Erb R, et al. 2001. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9(1): 58-66.
20. Sajatovic M, Friedman SJ, Sabharwal J, Bingham CR. 2004. Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression and dementia. Int J Psychiatry Neurol 17(1): 3-8.
21. Sheehan DV, Lecubier Y, Sheehan KH, et al. 1998. Development and validation of a structured diagnositic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59C(Suppl. 20): 22-23.
22. Simpson GM, Angus JWS. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
23. Sink KM, Holden KF, Yaffe K. 2005. Macological treatment of neuropyschiatric symptoms of dementia: a review of the evidence. JAMA 293(5): 596-608.
24. Sival RC, Haffmans PM, Jansen PA, et al. 2002. Sodium valproate in the treatment of aggressive behavior in paitents with dementia - a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 17(96): 579-585.
25. Stahl SM. 2004. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry 65(6): 738-739.
26. Tariot PN, Raman R, Jakimovich L, et al. 2005. Divalproex sodium in nursing home residents with possible or probably Alzheimer disease complicated by agitation. Am J Geriatr Psychiatry 13(11): 942-949.
27. Townsend MH, Wilson MS. 2005. Comorbid anxiety disorders and divalproex sodium use among partial hospital patients with psychotic disorders. Compr Psychiatry 46(5): 368-370.
28. US Department of Health, Education and Welfare. ECDEU Assessment Manual for Psychopharmacology, Revised edn, Guy W. 1976. Publication ADM 76-338.US Department of Health, Education and Welfare: Washington, DC.
29. Ware JE, Sherbourne CD. 1992. The MOS 36-item short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection. Med Care 30(6): 473-483.
30. Wassef A, Baker J, Kochan LD. 2003. GABA and schizophrenia; a review of basic science and clinical studies. J Clin Psychopharmacol 23(96): 601-640.
31. Wassef AA, Dott SG, Harris A, et al. 1999. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 19(3): 222-232.
32. Wassef AA, Dott SG, Harris A, et al. 2000. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 20(3): 357-361.
33. Yesavage JA, Brink TL, Rose TL, et al. 1982. Development and Validation of a Geriatric Depression screening Scale: A Preliminary Report. J Psychiatr Res 17(1): 37-49.